Back to Search
JONATHAN RICKER, DO
DO
Gastroenterology Physician
NPI: 1396843496IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
DO1670(NV)
Gastroenterology PhysicianPrimary
Internal Medicine — Gastroenterology
Code: 207RG0100X
DO1670(NV)
CMS Specialties
PrimaryGASTROENTEROLOGY
Education
LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Class of 2004
Research & Publications (20)
Building a research program in rehabilitation sciences, Part II: case studies: University of Texas Medical Branch, Boston University, University of Pittsburgh, and University of Washington.
PMID 19620833·Am J Phys Med Rehabil·2009
8-other
Feasibility of a brief neuropsychologic test battery during acute inpatient rehabilitation after traumatic brain injury.
PMID 18452744·Arch Phys Med Rehabil·2008
4-observational
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
PMID 18296419·Ann Oncol·2008
3-trial
Inflammatory bowel disease: thinking outside of the intestines (Part 1).
PMID 19297931·J Miss State Med Assoc·2008
6-review
Inflammatory bowel disease: thinking outside of the intestines (Part 2).
PMID 19297932·J Miss State Med Assoc·2008
6-review
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
PMID 18297527·Leuk Lymphoma·2008
3-trial
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
PMID 18645005·Mol Cancer Ther·2008
7-preclinical
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
PMID 18425418·Invest New Drugs·2008
3-trial
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
PMID 17962510·Blood·2008
3-trial
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
PMID 17960324·Invest New Drugs·2008
3-trial
The predictive validity of a brief inpatient neuropsychologic battery for persons with traumatic brain injury.
PMID 18452745·Arch Phys Med Rehabil·2008
8-other
Applications of functional near-infrared spectroscopy (fNIRS) to Neurorehabilitation of cognitive disabilities.
PMID 17366277·Clin Neuropsychol·2007
6-review
Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.
PMID 17405170·Head Neck·2007
6-review
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
PMID 16960145·Blood·2007
3-trial
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
PMID 17577020·J Clin Oncol·2007
3-trial
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
PMID 16466850·Cancer Lett·2007
8-other
Equine sperm membrane phase behavior: the effects of lipid-based cryoprotectants.
PMID 16251500·Biol Reprod·2006
7-preclinical
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
PMID 17145826·Clin Cancer Res·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 825 N GIBSON RD STE 201
HENDERSON, NV 89011 - Phone
- (702) 492-1162
Quick Facts
- NPI
- 1396843496
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 22
- Publications
- 20
Are you this provider?
Claim Your Profile